Compare AMCX & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | EBS |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.2M | 413.3M |
| IPO Year | 2011 | 2006 |
| Metric | AMCX | EBS |
|---|---|---|
| Price | $9.79 | $7.26 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $7.33 | ★ $12.00 |
| AVG Volume (30 Days) | 469.7K | ★ 772.3K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | 125.83 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $2,311,801,000.00 | $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $107.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.41 | $5.62 |
| 52 Week High | $11.13 | $14.06 |
| Indicator | AMCX | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 36.25 |
| Support Level | $9.31 | N/A |
| Resistance Level | $10.38 | $8.59 |
| Average True Range (ATR) | 0.47 | 0.28 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 33.95 | 2.09 |
AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.